Today, this update is sent with so much gratitude in our hearts. The Lynn Sage Foundation has reached a major milestone because of your generosity and support. We are thrilled to announce that The Foundation will sponsor two Lynn Sage Scholars and expand its funding to Rush University Medical Center in 2017!
Congratulations to Dr. Marc L. Mendillo, PhD at Northwestern University Feinberg School of Medicine and Dr. Abde Abukhdeir, PhD of Rush University Medical Center! We are excited to welcome such talented doctors into the Lynn Sage Scholars program. Please see below for more details about their exciting research.
As a reminder, the Lynn Sage Scholars program funds $100,000 core scholarships annually to chosen candidates in the field of breast cancer for a maximum of two years. In 2017, we will simultaneously fund two Scholars for the first time, by continuing our partnership with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and embarking on a new relationship with Rush University Medical Center.
Please know what a difference you're making in the quest to end breast cancer. Thank you so much for your continued support!
Laura & Halee
Dr. Mendillo’s Research Program
The cellular stress response network promotes tumor progression, metastasis and drug resistance. At Northwestern, Dr. Mendillo is driven to study and define the operating principles of this network and reveal vulnerabilities that can be exploited for new approaches to diagnose and treat breast cancer. Dr. Mendillo is committed to ultimately bring forth breakthroughs that will propel the next generation of treatments and approaches against cancer.
Dr. Mendillo is an Assistant Professor of Biochemistry and Molecular Genetics. He joined Northwestern University Feinberg School of Medicine in 2015. Dr. Mendillo received his PhD from the University of California, San Diego and subsequently completed fellowships at the Ludwig Institute for Cancer Research and the Whitehead Institute at MIT prior to arriving at the Lurie Cancer Center.
Dr. Abukhdeir’s Research Program
Dr. Abukhdeir’s research group investigates molecular variants that lead to or contribute to drug resistance in breast cancer. These molecular variants have the potential to serve as predictive biomarkers or novel targets for therapies. His group has identified a group of genes whose expression can predict which patients will respond to trastuzumab therapy. More recently, they have repurposed drugs that block key growth signaling pathways for use in breast cancer.
Dr. Abukhdeir is currently an assistant professor of Medicine and Pharmacology at Rush University Medical Center. He completed his Ph.D. at Loyola University. He then went on to complete a postdoctoral fellowship at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, where he identified mechanisms of tamoxifen resistance and published several papers in high-profile journals, including Proceedings of National Academy of Sciences and Blood. Later, he transitioned into a junior faculty member, where Dr. Abukhdeir collaborated with the Stand Up to Cancer Epigenetic Dream Team to identify molecular predictors of response to epigenetic therapies. In 2012, Dr. Abukhdeir moved to Rush University to begin an independent faculty appointment.